Vericel (VCEL) reported Q4 net income Thursday of $0.38 per diluted share, up from $0.26 a year earlier.

Analysts polled by FactSet expected $0.32.

Revenue for the quarter ended Dec. 31 was $75.4 million, up from $65.0 million a year earlier.

Analysts surveyed by FactSet expected $76.5 million.

For 2025, the biopharmaceutical company expects net revenue to increase 20% to 23%. Analysts polled by FactSet expect $289.8 million.

Additionally, the company said it had cash, restricted cash and investments of about $167 million as of Dec. 31, and no debt.

Vericel shares were down 4.7% in recent premarket activity.